Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (301-310 of 520) with videos related to

Pageof 52
Sort By:
JAMA Cardiology|September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure ManagementAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Heart Failure|February 4, 2022
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HFAlexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, et al.
Circulation. Heart Failure|December 21, 2018
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
European Journal of Heart Failure|April 10, 2026
Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT AmericasIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
International Journal of Cardiology|February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCATJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
Pageof 52

Showing results (301-310 of 520) with videos related to

Sort By:
Pageof 52
JAMA Cardiology|September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure ManagementAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Heart Failure|February 4, 2022
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HFAlexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, et al.
Circulation. Heart Failure|December 21, 2018
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
European Journal of Heart Failure|April 10, 2026
Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT AmericasIris E Beldhuis, Brian L Claggett, Brendon L Neuen, et al.
International Journal of Cardiology|February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCATJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
Diabetes, Obesity & Metabolism|December 22, 2022
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trialHertzel C Gerstein, Emil Wolsk, Brian Claggett, et al.
American Heart Journal|February 23, 2020
Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapibJean-Claude Tardif, Marie-Pierre Dubé, Marc A Pfeffer, et al.
Pageof 52